Table 2.
Details of DFS and OS events stratified by different groups.
| Overall n = 1305 (%) | HER2-neg n = 1078 (%) | HER2-pos-T n = 227 (%) | |
|---|---|---|---|
| DFS events | |||
| No recurrence | 1131 (86.6) | 921 (85.4) | 210 (92.5) |
| Local-regional recurrence | 28 (2.1) | 25 (2.3) | 3 (1.3) |
| Contralateral breast cancer | 14 (1.1) | 12 (1.1) | 2 (0.9) |
| Second non-breast malignancy | 23 (1.8) | 22 (2.0) | 1 (0.4) |
| Distant metastasis | 78 (6.0) | 72 (6.7) | 6 (2.6) |
| Death without recurrence | 31 (2.4) | 26 (2.4) | 5 (2.2) |
| OS events | |||
| Alive | 1237 (94.7) | 1017 (94.3) | 220 (96.9) |
| Death of any cause | 69 (5.3) | 62 (5.7) | 7 (3.1) |
| Death with recurrence | 38 (2.9) | 36 (2.3) | 2 (0.9) |
| Death without recurrence | 31 (2.4) | 26 (2.4) | 5 (2.2) |
Abbreviations: HER2, human epidermal growth factor receptor 2; DFS: disease-free survival; OS: overall survival.